Clinical Trial: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07005128) titled 'A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)' on May 27.

Brief Summary: The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Study Start Date: June 20

Study Type: INTERVENTIONAL

Condition: Small-cell Lung Cancer Extensive Stage Small-cell Lung Cancer

Intervention: DRUG: Tarlatamab

Tarlatamab will be administered as an intrav...